Metoprolol Succinate
Product Images NDC 71610-483

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Metoprolol Succinate (NDC 71610-483). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 25 mg (71610 0483 45)

Label for Metoprolol Succinate ER 25 mg tablets showing the NDC code 73160-0483-45. The label includes storage instructions, manufacturer AstraZeneca AB in Sodertalje, Sweden, and packaging by Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The package contains 45 tablets and is marked RX Only.*

FDA Label Image

Bottle Label 100 mg (71610 0484 45)

METOPROLOL SUCCINATE ER 100 mg tablets packaging label showing 45 tablets per container. The label includes storage instructions, manufacturer AstraZeneca AB in Sweden, and repackager Aphena Pharma Solutions - Tennessee, LLC in Cookeville, TN. The label also contains barcodes, lot number, and expiration date.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Structuralformula (Image 01)

Chemical structure of metoprolol succinate showing two metoprolol molecules bonded to a succinate molecule as represented by the bracketed structural formula with hydroxyl, ether, amine, and carboxyl functional groups.*

FDA Label Image

Merit Graphic (Image 02)

A forest plot titled 'Results for Subgroups in MERIT-HF' showing relative risk and 95% confidence intervals for three outcomes: Total Mortality, Total Mortality or All-Cause Hospitalization (Time to First Event), and Total Mortality or Hospitalization for Heart Failure (Time to First Event). The subgroups listed include geographic location, NYHA class, ejection fraction, etiology, sex, race, history of myocardial infarction, diabetes, hypertension, and heart rate. Each subgroup comparison shows a relative risk with confidence intervals favoring metoprolol succinate extended release tablets or placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.